Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03068754 · ClinicalTrials.gov registry record · Phase 2
Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)
A Phase 2 study, sponsored by Mallinckrodt.
- Terminated
- Registry status
- Phase 2
- Development phase
- 143
- Enrollment target
NCT03068754 is a Phase 2 study that was terminated before completion, run by Mallinckrodt. The registered enrollment target is 143 participants.
The verdict
NCT03068754, a Phase 2 study, was terminated before completion, sponsored by Mallinckrodt.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 143 participants
- Enrollment target
Study Summary
About 213 people with ALS will participate in this study. There will be locations in North and South America. During the first part, participants will be randomly assigned to a group (like by flipping a coin). Out of every 3: * 2 will get the study drug * 1 will get a look-alike with no drug in it (placebo) During the second part, everyone will get the study drug. Participation will help doctors find out if Acthar can help or slow down the symptoms of ALS better than placebo.
Interventions
- DRUG Placebo
- DRUG Acthar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2017-06-22 |
| Est. Completion | 2019-11-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03068754
The ClinicalTrials.gov registry entry for NCT03068754 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 143 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mallinckrodt, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03068754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03068754 about?
NCT03068754 is a clinical study titled "Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS)". About 213 people with ALS will participate in this study. There will be locations in North and South America. During the first part, participants will be randomly assigned to a group (like by flipping a coin). Out of every 3: * 2 will get the study drug * 1 will get a look-alike with no drug in it...
What is the current status of trial NCT03068754?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 143 participants. The study started on 2017-06-22. Estimated completion is 2019-11-25.
What interventions are being tested in trial NCT03068754?
The interventions under investigation include: Placebo (DRUG), Acthar (DRUG).
Who is sponsoring clinical trial NCT03068754?
This trial is sponsored by Mallinckrodt, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.